News & Updates
Regulatory updates, research developments, and industry news.
State of Peptides 2026
A citation-heavy 2026 report on peptide demand, GLP-1 enforcement, FDA compounding policy, Category 2 peptide risk, and next-generation obesity trials.
Most Trending Peptides in 2026: What Demand Is Actually Concentrated Around
A practical, source-backed breakdown of the peptide categories attracting the most demand in 2026, from GLP-1 medicines and retatrutide to recovery and longevity peptides.
UK Peptide Regulation Check: No Standalone MHRA Peptide Guidance Found
A 2026 UK peptide regulation check: no standalone March 2026 MHRA peptide research-chemical guidance was found; current rules still turn on medicines law, specials, enforcement, and claims.
TGA Peptide Safety Update: Australia Focuses on Unapproved Products
Australia peptide regulation update: TGA warnings focus on unapproved peptide products, social-media claims, compounding responsibilities, and lawful access pathways.
FDA Peptide Compounding Status Update - May 2026 Audit
Current FDA peptide compounding signals as of May 2026, including Category 2 safety-risk language, 503A bulk-substance policy, and July 2026 PCAC review.
Peptide Market Growth in 2026: GLP-1s, Compounding Policy, and Quality Risk
A source-backed 2026 peptide market update focused on GLP-1 demand, FDA compounding policy, retatrutide trial momentum, Forzinity approval, and unapproved-product risk.
SS-31 Update: FDA Approval of Forzinity Changes the Elamipretide Story
Updated SS-31 and elamipretide news: FDA approved Forzinity for Barth syndrome in September 2025 under accelerated approval, based on a small Barth syndrome trial program.